Patents Assigned to IL Dong Pharmaceutical Co., Ltd.
  • Patent number: 11268064
    Abstract: The present invention relates to heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder, a preparation method therefor and a use thereof. The heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder of the present invention has an excellent therapeutic effect for atopic diseases, and particularly has high industrial applicability because membrane adhesion competitiveness, which is an advantage of existing lactic acid bacteria, is significantly improved, thereby exhibiting dermatitis preventing, alleviating and treating effects of the same level as steroid-based drugs.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: March 8, 2022
    Assignee: IL DONG PHARMACEUTICAL CO., LTD.
    Inventors: Seung-Hun Lee, Dae-Jung Kang, Jae-Hoon Kang
  • Patent number: 10988449
    Abstract: The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor (FXR, NR1H4).
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: April 27, 2021
    Assignee: IL DONG Pharmaceutical Co., Ltd.
    Inventors: Jae-Hoon Kang, Hong-Sub Lee, Yoon-Suk Lee, Jin-Ah Jeong, Sung-Wook Kwon, Jeong-Guen Kim, Kyung-Sun Kim, Dong-Keun Song, Sun-Young Park, Kyeo-Jin Kim, Ji-Hye Choi, Hey-Min Hwang
  • Patent number: 10919947
    Abstract: The present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-VEGF) agent are fused, for treating cancer or angiogenesis-related diseases. More specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti-vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-VEGF agent.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: February 16, 2021
    Assignee: IL DONG PHARMACEUTICAL CO., LTD.
    Inventors: Hyuk-Sang Kwon, Jong-Hee Ko, Young-Min Lee, Hyei-Yoon Jung, Seok-Woo Yang, Jae-Hoon Kang, Yong-Sung Kim
  • Patent number: 10443033
    Abstract: The present invention relates to heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder, a preparation method therefor and a use thereof. The heat-killed Lactobacillus rhamnosus conjugated to a polysaccharide polymer binder of the present invention has an excellent therapeutic effect for atopic diseases, and particularly has high industrial applicability because membrane adhesion competitiveness, which is an advantage of existing lactic acid bacteria, is significantly improved, thereby exhibiting dermatitis preventing, alleviating and treating effects of the same level as steroid-based drugs.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: October 15, 2019
    Assignee: IL DONG PHARMACEUTICAL CO., LTD.
    Inventors: Seung-Hun Lee, Dae-Jung Kang, Jae-Hoon Kang
  • Patent number: 5843735
    Abstract: Aklavinone C-11 hydroxylase separated from Streptomyces sp.; a gene encoding same; an expression vector comprising said gene; a microorganism transformed with said vector; and a process for preparing novel hybrid anthracyclines by using said vector.
    Type: Grant
    Filed: October 31, 1995
    Date of Patent: December 1, 1998
    Assignees: Korea Institute of Science and Technology, IL Dong Pharmaceutical Co., Ltd.
    Inventors: Jung-Joon Lee, Young-Ho Kim, Soon-Kwang Hong, Young-Soo Hong, Cheol-Kyu Hwang, Hang-Sub Kim